[144] Taysha Gene Therapies, Inc. SEC Filing

An insider of TSHA has filed a notice of proposed sale under Rule 144 to sell up to 100,846 shares of common stock through broker Maxim Group LLC around 01/23/2026 on Nasdaq.

Rhea-AI Filing Summary

An insider of TSHA has filed a notice of proposed sale under Rule 144 to sell up to 100,846 shares of common stock through broker Maxim Group LLC around 01/23/2026 on Nasdaq.

The shares were acquired on the same date via a vested RSU award from the issuer, with consideration described as the reporting person's continued service as an employee. The notice lists an aggregate market value of $513,306.14 for the planned sale and states that 273,919,373 common shares were outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the TSHA Rule 144 filing describe?

It describes a planned sale of 100,846 TSHA common shares by an insider under Rule 144, to be executed through broker Maxim Group LLC on Nasdaq.

How many TSHA shares are planned to be sold and at what value?

The filing lists 100,846 common shares to be sold, with an aggregate market value of $513,306.14 at the time of the notice.

How and when did the TSHA insider acquire the 100,846 shares?

The shares were acquired on 01/23/2026 via a restricted stock unit (RSU) award from the issuer, described as a vested grant settled in stock.

What was the consideration for the RSU award in the TSHA filing?

The consideration for the RSU award is stated as the reporting person’s continued service as an employee of the issuer.

How many TSHA shares were outstanding according to the filing?

The notice states that there were 273,919,373 TSHA common shares outstanding at the time referenced.

On which exchange and through which broker may the TSHA shares be sold?

The planned sale is listed for the Nasdaq exchange, through broker Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 07:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001793412
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TAYSHA GENE THERAPIES, INC.
SEC File Number	001-39536
Address of Issuer	3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TEXAS 75247
Phone	214-612-0000
Name of Person for Whose Account the Securities are To Be Sold	Kamran Alam
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	100846	513306.14	273919373	01/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	RSU Award	Issuer			100846	01/23/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Date of Notice	01/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kamran Alam
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)